Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Aspord

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Clinical and Molecular Hepatology|January 18, 2026
New Insights into Antibody-Mediated NK Cell Immunity in Hepatitis B: Editorial on "Dissecting antibody-mediated NK cell effects reveals a cytotoxic CX3CR1⁺KLRC2⁻CD16hi subset linked to HBV outcomes"Zuzana Macek Jilkova, Caroline Aspord
Journal of Autoimmunity|July 9, 2004
Early events in islets and pancreatic lymph nodes in autoimmune diabetesCaroline Aspord, Sophie Rome, Charles Thivolet
Medecine Sciences : M/S|March 20, 2026
[Metabolic rewiring of dendritic cells to re-invigorate antitumor immunity]Caroline Aspord, Camille Niveau, Philippe Saas
Cancers|September 23, 2020
Reply to Comment on "Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" <i>Cancers</i> 2019, <i>11</i>, 1554Zuzana Macek Jilkova, Caroline Aspord, Thomas Decaens
Cancers|October 17, 2019
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and ChallengesZuzana Macek Jilkova, Caroline Aspord, Thomas Decaens
Cancers|May 16, 2023
Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic ExploitationEleonora Sosa Cuevas, Philippe Saas, Caroline Aspord
European Journal of Immunology|July 22, 2014
pDCs efficiently process synthetic long peptides to induce functional virus- and tumour-specific T-cell responsesCaroline Aspord, Claire Leloup, Sabine Reche, et al.
Immunology|May 14, 2024
Glycans in melanoma: Drivers of tumour progression but sweet targets to exploit for immunotherapyCamille Niveau, Eleonora Sosa Cuevas, Philippe Saas, et al.
Cancer Immunology Research|April 30, 2014
Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSLCaroline Aspord, Marie-Therese Leccia, Julie Charles, et al.
Oncoimmunology|April 5, 2014
Melanoma hijacks plasmacytoid dendritic cells to promote its own progressionCaroline Aspord, Marie-Therese Leccia, Julie Charles, et al.
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Clinical and Molecular Hepatology|January 18, 2026
New Insights into Antibody-Mediated NK Cell Immunity in Hepatitis B: Editorial on "Dissecting antibody-mediated NK cell effects reveals a cytotoxic CX3CR1⁺KLRC2⁻CD16hi subset linked to HBV outcomes"Zuzana Macek Jilkova, Caroline Aspord
Journal of Autoimmunity|July 9, 2004
Early events in islets and pancreatic lymph nodes in autoimmune diabetesCaroline Aspord, Sophie Rome, Charles Thivolet
Medecine Sciences : M/S|March 20, 2026
[Metabolic rewiring of dendritic cells to re-invigorate antitumor immunity]Caroline Aspord, Camille Niveau, Philippe Saas
Cancers|September 23, 2020
Reply to Comment on "Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" <i>Cancers</i> 2019, <i>11</i>, 1554Zuzana Macek Jilkova, Caroline Aspord, Thomas Decaens
Cancers|October 17, 2019
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and ChallengesZuzana Macek Jilkova, Caroline Aspord, Thomas Decaens
Cancers|May 16, 2023
Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic ExploitationEleonora Sosa Cuevas, Philippe Saas, Caroline Aspord
European Journal of Immunology|July 22, 2014
pDCs efficiently process synthetic long peptides to induce functional virus- and tumour-specific T-cell responsesCaroline Aspord, Claire Leloup, Sabine Reche, et al.
Immunology|May 14, 2024
Glycans in melanoma: Drivers of tumour progression but sweet targets to exploit for immunotherapyCamille Niveau, Eleonora Sosa Cuevas, Philippe Saas, et al.
Cancer Immunology Research|April 30, 2014
Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSLCaroline Aspord, Marie-Therese Leccia, Julie Charles, et al.
Oncoimmunology|April 5, 2014
Melanoma hijacks plasmacytoid dendritic cells to promote its own progressionCaroline Aspord, Marie-Therese Leccia, Julie Charles, et al.
Pageof 7